Screening, Diagnose und Therapie alkoholbezogener Störungen: Was empfehlen die S3-Leitlinien der AWMF?

Martin Schäfer; Karl Mann; Friedrich Martin Wurst; und die Arbeitsgruppen „Screening und Diagnostik von Intoxikation, schädlichem und abhängigem Alkoholgebrauch“ (Friedrich M. Wurst [Leitung], Natasha Thon, Ulrich W. Preuss, Tim Neumann, Claudia Spies, Hans-Jürgen Rumpf, Karl Mann, Eva Hoch) und „Entgiftung, Entzug, Pharmakotherapie“ (Martin Schäfer [Leitung], Derik Herrmann, Gerhard Reymann, Clemens Veltrup, Bernd Wessel, Norbert Wodarz, Karl Mann, Eva Hoch, Welf Schröder, Arnold Wieczorek, Udo Bonnet)

doi:10.1055/s-0042-109481

PSYCH up2date, Inhaltsverzeichnis

PSYCH up2date 2016; 10(05): 351-370
DOI: 10.1055/s-0042-109481

Abhängigkeitserkrankungen

Screening, Diagnose und Therapie alkoholbezogener Störungen: Was empfehlen die S3-Leitlinien der AWMF?

Martin Schäfer

,

Karl Mann

,

Friedrich Martin Wurst

,

und die Arbeitsgruppen „Screening und Diagnostik von Intoxikation, schädlichem und abhängigem Alkoholgebrauch“ (Friedrich M. Wurst [Leitung], Natasha Thon, Ulrich W. Preuss, Tim Neumann, Claudia Spies, Hans-Jürgen Rumpf, Karl Mann, Eva Hoch) und „Entgiftung, Entzug, Pharmakotherapie“ (Martin Schäfer [Leitung], Derik Herrmann, Gerhard Reymann, Clemens Veltrup, Bernd Wessel, Norbert Wodarz, Karl Mann, Eva Hoch, Welf Schröder, Arnold Wieczorek, Udo Bonnet)

Abstract

Alle Artikel dieser Rubrik

Volltext

Referenzen

Literatur
1 Mann I, Hoch E, Batra A. S3-Leitlinie Screeing, Diagnose und Behandlung alkoholbezogener Störungen. Heidelberg: Springer; 2016
2 National Institute for Health and Clinical Excellence (NICE). Alcohol-use disorders: preventing the development of hazardous and harmful drinking – public health guidance (PH 24). London: National Institute for Health and Clinical Excellence; 2010
3 National Institute for Health and Clinical Excellence (NICE). Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence (CG 115). London: National Institute for Health and Clinical Excellence; 2011
4 Haber P, Lintzeris N, Proude E. et al. Guidelines for the treatment of alcohol problems. Sydney: Australian Government Department of Health and Ageing; 2009
5 Jackson R, Johnson M, Campbell F. et al. Screening and brief interventions for prevention and early identification of alcohol use disorders in adults and young people. Sheffield: School of Health and related Research (ScHARR); 2010
6 Rumpf HJ, Wohlert T, Freyer-Adam J. et al. Screening Questionnaires for Problem Drinking in Adolescents: Performance of AUDIT, AUDIT-C, CRAFFT and POSIT. European Addiction Research 2013; 19: 121-127
7 Sobell LC, Sobell MB. Alcohol Timeline Followback Userʼs? Manual. Toronto: Addiction Research Foundation; 1985
8 Dilling H, Mombour W, Schmidt MH, Schulte-Markwort E. Hrsg. Internationale Klassifikation psychischer Störungen: ICD-10, Kapitel V (F); Forschungskriterien. Bern: Huber; 1994
9 American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders. 5th. ed. Arlington, VA: American Psychiatric Publishing; 2013
10 Wittchen HU, Wunderlich U, Gruschwitz S. et al. SKID-I. Strukturiertes Klinisches Interview für DSM-IV. Achse I: Psychische Störungen. Göttingen: Hogrefe; 1997
11 Borges G, Ye Y, Bond J. et al. The dimensionality of alcohol use disorders and alcohol consumption in a cross-national perspective. Addiction 2010; 105: 240-254
12 Wurst FM, Thon N, Yegles M. et al. Ethanol metabolites: their role in the assessment of alcohol intake. Alcohol Clin Exp Res 2015; 39: 2060-2072
13 Aradottir S, Asanovska G, Gjerss S. et al. Phosphatidylethanol (PEth) concentrations in blood are correlated to reported alcohol intake in alcohol-dependent patients. Alcohol Alcoholism 2006; 41: 431-437
14 Anton RF, Stout RL, Roberts JS. et al. The effect of drinking intensity and frequency on serum carbohydrate-transferrin and gamma-glutamyl transferase levels in outpatient alcoholics. Alcohol Clin Exp Res 1998; 22: 1456-1462
15 Puukka K, Hietala J, Koivisto H. et al. Additive effects of moderate drinking and obesity on serum gamma-glutamyl transferase. Am J Clin Nutr 2006; 83: 1351-1354
16 Stibler H, Kjellin KG. Isoelectric focusing and electrophoresis of the CSF proteins in tremor of different origins. J Neurol Sci 1976; 30: 269-285
17 Burke V, Puddey IB, Rakic V. et al. Carbohydrate-deficient transferrin as a marker of change in alcohol intake in men drinking 20 to 60 g of alcohol per day. Alcohol Clin Exp Res 1998; 22: 1973-1980
18 Whitfield JB, Fletcher LM, Murphy TL. et al. Smoking, obesity and hypertension alter the dose-response curve and test sensitivity of carbohydrate-deficient transferrin as a marker of alcohol intake. Clin Chem 1998; 44: 2480-2489
19 Koivisto H, Hietala J, Anttila P. et al. Long-term ethanol consumption and macrocytosis: diagnostic and pathogenic implications. J Lab Clin Med 2006; 147: 191-196
20 Sillanaukee P, Olsson U. Improved diagnostic classification of alcohol abusers by combining carbohydrate-deficient transferrin and gamma-glutamyltransferase. Clin Chem 2001; 47: 681-685
21 Hietala J, Koivisto H, Anttila P. et al. Comparison of the combined marker GGTCDT and the conventional laboratory markers of alcohol abuse in heavy drinkers, moderate drinkers and abstainers. Alcohol Alcoholism 2006; 41: 528-533
22 Miller PM, Spies C, Neumann T. et al. Alcohol biomarker screening in medical and surgical settings. Alcoholism Clin Exp Res 2006; 30: 185-193
23 Brinkmann B, Köhler H, Banaschak S. et al. ROC analysis of alcoholism markers – 100 % specificity. Int J Legal Med 2000; 113: 293-299